Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting ...
Inovio Pharmaceuticals, Inc. ( INO) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 25, 2026 12:40 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results